CY1118573T1 - Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων - Google Patents
Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντωνInfo
- Publication number
- CY1118573T1 CY1118573T1 CY20161101335T CY161101335T CY1118573T1 CY 1118573 T1 CY1118573 T1 CY 1118573T1 CY 20161101335 T CY20161101335 T CY 20161101335T CY 161101335 T CY161101335 T CY 161101335T CY 1118573 T1 CY1118573 T1 CY 1118573T1
- Authority
- CY
- Cyprus
- Prior art keywords
- virus
- smallpox
- animal
- modified
- eyevology
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 241000700647 Variola virus Species 0.000 abstract 6
- 241001465754 Metazoa Species 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με την ταχεία επαγωγή μιας προστατευτικής ανοσολογικής απόκρισης έναντι ιών ευλογιάς και λοιμώξεων από ιό ευλογιάς όπως ευλογιά με εμβολιασμό ενός ζώου, συμπεριλαμβανομένου ενός ανθρώπου με έναν ιό ευλογιάς που είναι ανίκανος για αντιγραφή στο εν λόγω ζώο, συμπεριλαμβανομένου του ανθρώπου. Ένα παράδειγμα για έναν τέτοιον ιό της ευλογιάς είναι ένας Τροποποιημένος Ιός της Δαμαλίτιδας τύπου Ankara (MVA). Η εφεύρεση σχετίζεται περαιτέρω με τη χρήση ενός ανασυνδυασμένου ιού της ευλογιάς που είναι ανίκανος αντιγραφής στο ζώο, συμπεριλαμβανομένου του ανθρώπου που εμβολιάστηκε με τον ιό, όπως έναν ανασυνδυασμένο MVA που εκφράζει ετερόλογα αντιγόνα και/ή αντιγονικούς επιτόπους για την ταχεία επαγωγή μιας προστατευτικής ανοσολογικής απόκρισης έναντι του εν λόγω ετερόλογου αντιγόνου και/ή αντιγονικού επιτόπου, π.χ., έναντι ενός αντιγόνου και/ή αντιγονικού επιτόπου που είναι μέρος ενός μολυσματικού παράγοντα.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003873 | 2005-02-23 | ||
| EP06707039.1A EP1855720B2 (en) | 2005-02-23 | 2006-02-17 | Use of a modified proxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| PCT/EP2006/001447 WO2006089690A1 (en) | 2005-02-23 | 2006-02-17 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118573T1 true CY1118573T1 (el) | 2017-07-12 |
Family
ID=34933889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101335T CY1118573T1 (el) | 2005-02-23 | 2016-12-22 | Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20110142877A1 (el) |
| EP (1) | EP1855720B2 (el) |
| JP (3) | JP2008531489A (el) |
| KR (1) | KR20070110007A (el) |
| CN (1) | CN101128217B (el) |
| AU (1) | AU2006218115B2 (el) |
| BR (1) | BRPI0608310A2 (el) |
| CA (1) | CA2593532C (el) |
| CY (1) | CY1118573T1 (el) |
| DK (1) | DK1855720T4 (el) |
| EA (1) | EA013404B1 (el) |
| ES (1) | ES2608627T5 (el) |
| FI (1) | FI1855720T4 (el) |
| HK (1) | HK1113466A1 (el) |
| HU (1) | HUE030037T2 (el) |
| IL (1) | IL184347A (el) |
| LT (1) | LT1855720T (el) |
| MX (1) | MX2007010158A (el) |
| MY (1) | MY162027A (el) |
| NO (1) | NO347468B1 (el) |
| NZ (1) | NZ556409A (el) |
| PT (1) | PT1855720T (el) |
| SI (1) | SI1855720T2 (el) |
| UA (1) | UA100836C2 (el) |
| WO (1) | WO2006089690A1 (el) |
| ZA (1) | ZA200706078B (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006218115B2 (en) | 2005-02-23 | 2012-08-02 | Bavarian Nordic A/S | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| AU2007307080B2 (en) | 2006-10-06 | 2014-01-09 | Bavarian Nordic A/S | Methods for treating cancer with MVA |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP6480875B2 (ja) * | 2013-03-15 | 2019-03-13 | バヴァリアン・ノルディック・アクティーゼルスカブ | 単一高用量のｍｖａは、新生児及び幼児において防御免疫応答を引き起こす |
| US10653766B2 (en) | 2014-03-12 | 2020-05-19 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU782020B2 (en) * | 1999-11-12 | 2005-06-30 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| WO2004022729A1 (en) † | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| EE05680B1 (et) * | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
| AU2003239805B2 (en) | 2002-04-19 | 2009-09-10 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| JP4895505B2 (ja) * | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 |
| EP1575611A4 (en) * | 2002-12-23 | 2007-10-03 | Hope City | VACCINIA ANKARA MODIFIED EXPRESSING P53 IN IMMUNOTHERAPY OF CANCER |
| US6960345B2 (en) * | 2003-03-06 | 2005-11-01 | Incell Corporation, Llc | Oral vaccinia formulation |
| EP2359851A3 (en) * | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| AU2006218115B2 (en) * | 2005-02-23 | 2012-08-02 | Bavarian Nordic A/S | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
-
2006
- 2006-02-17 AU AU2006218115A patent/AU2006218115B2/en active Active
- 2006-02-17 NO NO20074855A patent/NO347468B1/no unknown
- 2006-02-17 ES ES06707039T patent/ES2608627T5/es active Active
- 2006-02-17 HU HUE06707039A patent/HUE030037T2/en unknown
- 2006-02-17 FI FIEP06707039.1T patent/FI1855720T4/fi active
- 2006-02-17 EP EP06707039.1A patent/EP1855720B2/en active Active
- 2006-02-17 UA UAA200710500A patent/UA100836C2/ru unknown
- 2006-02-17 LT LTEP06707039.1T patent/LT1855720T/lt unknown
- 2006-02-17 SI SI200632128T patent/SI1855720T2/sl unknown
- 2006-02-17 NZ NZ556409A patent/NZ556409A/en unknown
- 2006-02-17 KR KR1020077017385A patent/KR20070110007A/ko active Search and Examination
- 2006-02-17 BR BRPI0608310-2A patent/BRPI0608310A2/pt not_active Application Discontinuation
- 2006-02-17 EA EA200701801A patent/EA013404B1/ru not_active IP Right Cessation
- 2006-02-17 PT PT67070391T patent/PT1855720T/pt unknown
- 2006-02-17 JP JP2007555533A patent/JP2008531489A/ja active Pending
- 2006-02-17 MX MX2007010158A patent/MX2007010158A/es active IP Right Grant
- 2006-02-17 WO PCT/EP2006/001447 patent/WO2006089690A1/en active Search and Examination
- 2006-02-17 CA CA2593532A patent/CA2593532C/en active Active
- 2006-02-17 DK DK06707039.1T patent/DK1855720T4/da active
- 2006-02-17 CN CN2006800058754A patent/CN101128217B/zh active Active
- 2006-07-20 MY MYPI20063481A patent/MY162027A/en unknown
-
2007
- 2007-07-02 IL IL184347A patent/IL184347A/en active IP Right Grant
- 2007-07-23 ZA ZA2007/06078A patent/ZA200706078B/en unknown
- 2007-08-23 US US11/892,479 patent/US20110142877A1/en not_active Abandoned
-
2008
- 2008-04-02 HK HK08103647.3A patent/HK1113466A1/xx unknown
-
2011
- 2011-12-22 US US13/335,097 patent/US8808709B2/en active Active
-
2012
- 2012-07-10 JP JP2012154752A patent/JP5952112B2/ja active Active
-
2014
- 2014-07-10 US US14/328,474 patent/US9265823B2/en active Active
-
2016
- 2016-03-03 JP JP2016041014A patent/JP2016104822A/ja active Pending
- 2016-12-22 CY CY20161101335T patent/CY1118573T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118573T1 (el) | Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων | |
| CY1122872T1 (el) | Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| CY1124015T1 (el) | Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδiκευοντας ενα ετερολογο αντιγονο που απομονωνεται απο ιο ηπατιτιδας β και χρησεις εξ αυτων | |
| CY1121215T1 (el) | Αντιικα εμβολια με βελτιωμενη κυτταρικη ανοσογονικοτητα | |
| EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| WO2017147553A3 (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| CY1113540T1 (el) | Εμβολια γριππης σκυλων | |
| DE60144240D1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
| CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
| MX2019007349A (es) | Vacuna combinada para cerdos. | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| AR080111A1 (es) | Metodos y composiciones de inmunizacion | |
| CL2021002727A1 (es) | Vacuna con subunidades del vfpc | |
| PH12018502436A1 (en) | Multivalent vaccines major swine viral diseases | |
| MX2022007398A (es) | Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas. | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| Miura et al. | Efficacy of recombinant canine distemper virus expressing leishmania antigen against leishmania challenge in dogs | |
| WO2016130560A3 (en) | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats | |
| BR112018015912A2 (pt) | vírus da vacina da síndrome respiratória e reprodutiva porcina | |
| BR112017019776A2 (pt) | proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos | |
| AR124385A1 (es) | Parapoxvirus modificado que tiene una inmunogenicidad aumentada | |
| UY31574A1 (es) | Vacunas contra la malaria |